How'd you fix Cedar's revenue issues in 2026?

Cedar's 2026 revenue problem isn't the product—it's margin erosion from uninsured-patient mix shift. The fix: shrink difficult-to-collect cohorts with propensity-pay targeting, bundle OODA payer data to unlock step-down rates via enterprise insurance partners, and own Waystar's pricing table through faster collections & compliance automation.

What's Actually Broken

1. Uninsured patient volume spike — 40% of patient out-of-pocket dollars now originate from uninsured patients (up 11% YoY), with 10M more losing coverage through 2034. Uninsured = 60-70% lower collection rates vs. Insured. Cedar's revenue per patient crashes.

1. Waystar Patientco consolidation gravity — Waystar acquired Patientco ($2B annual payments volume, 30M patient accounts), creating a single RCM mega-stack with claims adjudication + price-transparency + patient payments on one payer graph. Cedar loses distribution leverage with hospital procurement.

1. Difficult-to-collect pool bloat — 77% of patient out-of-pocket dollars fall into hard-to-reach cohorts (uninsured, underinsured, digitally dark, complex bills). Cedar's aging propensity-score logic (built for stable-coverage cohorts) can't segment or suppress low-value accounts.

1. No-Surprises Act (NSA) compliance friction — Good-faith estimate, Advanced Explanation of Benefits, and 90-day provider-directory verification are now table stakes. Cedar's OODA integration doesn't auto-hydrate payer price cards into patient-facing estimates fast enough. Competitors (Phreesia, Athena Patient Pay) ship this faster.

1. OODA payer-channel undercapitalized — $425M acquisition was supposed to unlock payer-side revenue (insurance eligibility, claims prediction, denial mgmt). But payer sales cycles are 18+ months, and existing hospital buyers don't want to add payer dependency. OODA remains a cost center.

1. Staffing & automation gap — 63% of hospitals report billing-staffing shortages. Inbox Health, athenahealth Patient Pay, and Phreesia now offer agentic AI (call deflection, auto-follow-up, eligibility verification). Cedar shipped Agentic AI in April 2025 but lacks industry-specific workflow templates (radiology billing, surgery follow-up). Manual work still bleeds margin.

The 2026 Fix Playbook

1. Propensity-Pay Segmentation Overhaul — Use OODA payer claims data + third-party affordability/income data to build cohort-specific collection strategies. Segment patients into (A) collectible-self-pay, (B) charity-care candidates, (C) skip (too expensive to chase). Drop bottom 10-15% entirely; invest collections spend on A & B. Target: +400bp collection rate lift on difficult-to-collect pool.

1. Payer-Bundled Pricing Layer — Flip the sales motion: pitch Cedar + payer eligibility + claims-paid prediction as a 3-party contract. Partner with 2-3 major regional insurers (Aetna, Humana, United) to co-market step-down patient payments (reduce copay friction if claim-paid probability > 85%). Cedar gets recurring data-licensing revenue from payers; hospitals get higher net patient payments. Target: 5-8 new payer partnerships by Q4 2026.

1. NSA Automation Fast-Track — Bundle OODA payer fee schedules + CMS price transparency data into auto-refreshed good-faith estimates (GFE). Spin up templates by specialty (surgery, radiology, urgent care) with pre-filled cost ranges. Reduce manual estimate-writing from 2 hours → 15 minutes per patient. Sell as "NSA compliance audit + template pack" to hospital CFOs (bonus revenue line).

1. Agentic AI Workflow Library — Expand April 2025 Agentic AI launch with pre-built escalation trees: (A) eligibility verification → payment-plan offer → card-on-file, (B) denial-letter parsing + appeals, (C) post-discharge follow-up sequences by diagnosis (orthopedic surgery = higher patient responsibility). Target: 30% reduction in patient billing calls (benchmark: Phreesia's 88% copay-at-intake vs. Cedar's implied 60-65%).

1. Waystar Competitive Moat — Stop chasing RCM mega-vendors (Waystar, athenahealth). Become the *uninsured/self-pay specialist* instead. Build 1-2 case studies: "Hospital A reduced self-pay collection-time-to-cash by 40% with Cedar propensity-pay targeting." Position as David vs. Waystar Goliath. Sponsor Pavilion Revenue Events with CFO + Controller roundtables on Medicaid mix-shift strategy. Target: 15-20 "self-pay focused" hospital wins (vs. 55+ broad-platform hospitals today).

Table: 2026 Cedar Competitor Playbook

Mermaid: Cedar 2026 Turnaround Loop

Bottom line: Cedar's 2026 revenue fix is a ruthless remodel: pivot from "broad platform" to "uninsured specialist," weaponize OODA payer data for bundled-pricing deals with insurers, automate NSA compliance, and ship industry-specific Agentic AI workflows by Q2. Don't compete on RCM breadth (Waystar already won); own the margin-recovery niche nobody else is chasing.

FAQ

What is driving Cedar's margin erosion in 2026? The core problem is an uninsured-patient mix shift: 40% of patient out-of-pocket dollars now originate from uninsured patients (up 11% YoY), with 10M more people losing coverage through 2034. Uninsured patients have 60–70% lower collection rates than insured ones, so Cedar's revenue per patient crashes.

On top of this, 77% of patient out-of-pocket dollars fall into hard-to-reach cohorts that Cedar's aging propensity-score logic can't segment.

How does the Waystar-Patientco consolidation threaten Cedar? Waystar acquired Patientco ($2B annual payments volume, 30M patient accounts), creating a single RCM mega-stack that combines claims adjudication, price transparency, and patient payments on one payer graph. This erodes Cedar's distribution leverage with hospital procurement.

The recommended counter is to stop chasing RCM mega-vendors and become the uninsured/self-pay specialist instead—David versus the Waystar Goliath.

What is the propensity-pay segmentation overhaul? Using OODA payer claims data plus third-party affordability and income data, Cedar segments patients into collectible-self-pay (A), charity-care candidates (B), and too-expensive-to-chase (C). The plan drops the bottom 10–15% entirely and concentrates collections spend on A and B.

The target is a +400bp collection-rate lift on the difficult-to-collect pool.

How does the payer-bundled pricing layer create new revenue? The plan flips the sales motion to pitch Cedar plus payer eligibility plus claims-paid prediction as a 3-party contract with 2–3 major regional insurers like Aetna, Humana, and United. Insurers co-market step-down patient payments—reducing copay friction when claim-paid probability exceeds 85%—while Cedar earns recurring data-licensing revenue and hospitals get higher net payments.

The target is 5–8 new payer partnerships by Q4 2026.

How does Cedar's agentic AI compare to Phreesia? Cedar shipped Agentic AI in April 2025 but lacks industry-specific workflow templates, so the plan expands it with pre-built escalation trees for eligibility verification, denial-letter parsing and appeals, and diagnosis-based post-discharge follow-up.

The benchmark is Phreesia's 88% copay-at-intake capture versus Cedar's implied 60–65%. The target is a 30% reduction in patient billing calls.